Lates News

The experimental drug "Ritatide" from Lilly Company for the treatment of obesity has shown weight loss effects superior to any other drug currently on the market, highlighting the potential of this drug in the increasingly fierce competition of next-generation therapies. Lilly Company announced on Thursday that patients taking the highest dose of Ritatide (including those who discontinued treatment) had an average weight loss of 15.3%. These late-stage trial results were significantly better than the company's previous diabetes blockbuster drug "Mufenda". Lilly stated that weekly injections of this injectable can lower blood sugar by 1.9% over approximately nine months, a similar effect to the approved "Mufenda" in 2022. "Ritatide" is one of the core strategies in Lilly Company's obesity treatment plan, with analysts estimating its sales could exceed $10.6 billion by 2036.